$IMVT
Immunovant, Inc.

2021 Q1 Form 10-Q Financial Statement

#000176401321000018 Filed on February 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.30M $10.55M $6.090M
YoY Change 62.97% 73.23%
% of Gross Profit
Research & Development $18.62M $21.09M $4.953M
YoY Change 31.4% 325.82% -35.53%
% of Gross Profit
Depreciation & Amortization $30.00K $20.00K $20.00K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $28.92M $31.64M $11.04M
YoY Change 41.21% 186.57% 24.28%
Operating Profit
YoY Change
Interest Expense $0.00 $0.00 $376.0K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $680.0K -$503.0K $221.0K
YoY Change -623.08% -327.6% 413.95%
Pretax Income -$28.24M -$32.14M -$11.20M
YoY Change 37.02% 187.09% 26.64%
Income Tax -$80.00K -$367.0K $100.0K
% Of Pretax Income
Net Earnings -$28.16M -$31.78M -$11.30M
YoY Change 37.03% 181.3% 27.65%
Net Earnings / Revenue
Basic Earnings Per Share -$0.32
Diluted Earnings Per Share -$288.0K -$0.32 -$275.3K
COMMON SHARES
Basic Shares Outstanding 97.97M shares 97.92M shares 14.38M shares
Diluted Shares Outstanding 97.92M shares

Balance Sheet

Concept 2021 Q1 2020 Q4 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $400.1M $422.0M $123.5M
YoY Change 297.71% 241.7%
Cash & Equivalents $400.1M $422.0M $123.5M
Short-Term Investments
Other Short-Term Assets $8.300M $7.000M $0.00
YoY Change 50.91%
Inventory
Prepaid Expenses $7.716M $6.973M $44.00K
Receivables $596.0K
Other Receivables
Total Short-Term Assets $409.0M $429.4M $126.6M
YoY Change 274.97% 239.28%
LONG-TERM ASSETS
Property, Plant & Equipment $201.0K $132.0K $49.00K
YoY Change 209.23% 169.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $3.483M $3.601M $49.00K
YoY Change 1019.94% 7248.98%
TOTAL ASSETS
Total Short-Term Assets $409.0M $429.4M $126.6M
Total Long-Term Assets $3.483M $3.601M $49.00K
Total Assets $412.5M $433.0M $126.6M
YoY Change 277.09% 241.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.432M $2.100M $2.812M
YoY Change 104.37% -25.32%
Accrued Expenses $15.16M $13.28M $8.705M
YoY Change 38.6% 52.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.77M $16.49M $14.80M
YoY Change 22.54% 11.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.200M $2.400M
YoY Change
Total Long-Term Liabilities $2.200M $2.400M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $18.77M $16.49M $14.80M
Total Long-Term Liabilities $2.200M $2.400M $0.00
Total Liabilities $21.01M $18.88M $14.76M
YoY Change 37.15% 27.92%
SHAREHOLDERS EQUITY
Retained Earnings -$198.7M -$170.5M -$70.68M
YoY Change 117.76% 141.25%
Common Stock $10.00K $10.00K $5.000K
YoY Change 100.0% 100.0% 1636.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $391.5M $414.2M $111.9M
YoY Change
Total Liabilities & Shareholders Equity $412.5M $433.0M $126.6M
YoY Change 277.09% 241.99%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2019 Q4
OPERATING ACTIVITIES
Net Income -$28.16M -$31.78M -$11.30M
YoY Change 37.03% 181.3% 27.65%
Depreciation, Depletion And Amortization $30.00K $20.00K $20.00K
YoY Change 0.0%
Cash From Operating Activities -$22.50M -$22.81M -$29.78M
YoY Change -2.39% -23.4%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K -$30.00K -$20.00K
YoY Change 800.0% 50.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$90.00K -$30.00K $115.0M
YoY Change 800.0% -100.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 760.0K 450.0K 30.05M
YoY Change 660.0% -98.5%
NET CHANGE
Cash From Operating Activities -22.50M -22.81M -29.78M
Cash From Investing Activities -90.00K -30.00K 115.0M
Cash From Financing Activities 760.0K 450.0K 30.05M
Net Change In Cash -21.83M -22.39M 115.3M
YoY Change -4.92% -119.43%
FREE CASH FLOW
Cash From Operating Activities -$22.50M -$22.81M -$29.78M
Capital Expenditures -$90.00K -$30.00K -$20.00K
Free Cash Flow -$22.41M -$22.78M -$29.76M
YoY Change -2.73% -23.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001764013
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Registrant Name
EntityRegistrantName
IMMUNOVANT, INC.
dei Entity Shell Company
EntityShellCompany
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38906
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2771572
dei Entity Address Address Line1
EntityAddressAddressLine1
320 West 37th Street
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10018
dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei City Area Code
CityAreaCode
917
dei Local Phone Number
LocalPhoneNumber
580-3099
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
IMVT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3469000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
97971243 shares
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
421974000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100571000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6973000 USD
CY2020Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5460000 USD
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
481000 USD
CY2020Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
36000 USD
CY2020Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
0 USD
CY2020Q1 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
3009000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
429428000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
109076000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
132000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65000 USD
CY2020Q4 us-gaap Deferred Costs
DeferredCosts
0 USD
CY2020Q1 us-gaap Deferred Costs
DeferredCosts
246000 USD
CY2020Q4 us-gaap Assets
Assets
433029000 USD
CY2020Q1 us-gaap Assets
Assets
109387000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2100000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1190000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13281000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10938000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1104000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0 USD
CY2020Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3190000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16485000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15318000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2392000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q4 us-gaap Liabilities
Liabilities
18877000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
15318000 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2020Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2020Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97971243 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97971243 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56455376 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54655376 shares
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
10000 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
5000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
584174000 USD
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
185306000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
467000 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-170499000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91226000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
414152000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
94069000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
433029000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109387000 USD
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21091000 USD
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4953000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49989000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33759000 USD
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10549000 USD
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6088000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29211000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11836000 USD
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
31640000 USD
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
11041000 USD
us-gaap Operating Expenses
OperatingExpenses
79200000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-352000 USD
us-gaap Operating Expenses
OperatingExpenses
45595000 USD
CY2020Q4 us-gaap Interest Expense
InterestExpense
0 USD
CY2019Q4 us-gaap Interest Expense
InterestExpense
376000 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
625000 USD
CY2020Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-503000 USD
CY2019Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
221000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
539000 USD
CY2020Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-32143000 USD
CY2019Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-11196000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-79552000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-45681000 USD
CY2020Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-367000 USD
CY2019Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-279000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
156000 USD
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-31776000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-11296000 USD
us-gaap Net Income Loss
NetIncomeLoss
-79273000 USD
us-gaap Net Income Loss
NetIncomeLoss
-45837000 USD
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2020Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
97920460 shares
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41035055 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
84413511 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39408236 shares
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-31776000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-11296000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-11296000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-11296000 USD
us-gaap Net Income Loss
NetIncomeLoss
-79273000 USD
us-gaap Net Income Loss
NetIncomeLoss
-45837000 USD
CY2020Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
689000 USD
CY2019Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-149000 USD
CY2019Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-149000 USD
CY2019Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-149000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
483000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-493000 USD
CY2020Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
689000 USD
CY2019Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-149000 USD
CY2019Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-149000 USD
CY2019Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-149000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
483000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-493000 USD
CY2020Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31087000 USD
CY2019Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11445000 USD
CY2019Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11445000 USD
CY2019Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11445000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78790000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46330000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
94069000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63000 USD
CY2020Q2 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
63000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3918000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
26000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-26708000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
267775000 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
119000 USD
CY2020Q3 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
54000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3307000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-232000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-20789000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
438406000 USD
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
725000 USD
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5992000 USD
CY2020Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
689000 USD
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-31776000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
414152000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
7339000 USD
CY2019Q2 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
35000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
537000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-291000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-20059000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-12108000 USD
CY2019Q3 imvt Settlement Of Common Shares Subscription
SettlementOfCommonSharesSubscription
3000 USD
CY2019Q3 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
18000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3119000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-53000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-14482000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-23283000 USD
CY2019Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
35587000 USD
CY2019Q4 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
109277000 USD
CY2019Q4 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
82000 USD
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1332000 USD
CY2019Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-149000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-11296000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
111862000 USD
us-gaap Net Income Loss
NetIncomeLoss
-79273000 USD
us-gaap Net Income Loss
NetIncomeLoss
-45837000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13334000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5123000 USD
us-gaap Depreciation
Depreciation
43000 USD
us-gaap Depreciation
Depreciation
15000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-483000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
493000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-13000 USD
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
0 USD
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
1628000 USD
imvt Gains Losses On Extinguishments Of Debts
GainsLossesOnExtinguishmentsOfDebts
0 USD
imvt Gains Losses On Extinguishments Of Debts
GainsLossesOnExtinguishmentsOfDebts
38000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
714000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1513000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2591000 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
445000 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-49000 USD
imvt Increase Decrease In Value Added Tax Receivable
IncreaseDecreaseInValueAddedTaxReceivable
-3009000 USD
imvt Increase Decrease In Value Added Tax Receivable
IncreaseDecreaseInValueAddedTaxReceivable
83000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
914000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2604000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2590000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3827000 USD
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
0 USD
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
188000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2917000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
7907000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
106000 USD
imvt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-687000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60831000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30307000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
115000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-115000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000 USD
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
333000 USD
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
867000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
907000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1236000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2500000 USD
imvt Cash Received On Recapitalization Transaction
CashReceivedOnRecapitalizationTransaction
0 USD
imvt Cash Received On Recapitalization Transaction
CashReceivedOnRecapitalizationTransaction
111016000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
382349000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
146873000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
321403000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
116545000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100571000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6985000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
421974000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123530000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4183000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
imvt Noncash Or Part Noncash Deferred Initial Public Offering Costs Included In Accrued Expenses
NoncashOrPartNoncashDeferredInitialPublicOfferingCostsIncludedInAccruedExpenses
0 USD
imvt Noncash Or Part Noncash Deferred Initial Public Offering Costs Included In Accrued Expenses
NoncashOrPartNoncashDeferredInitialPublicOfferingCostsIncludedInAccruedExpenses
574000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
35000000 USD
imvt Forgiveness Of Interest On Convertible Promissory Notes Recorded In Equity
ForgivenessOfInterestOnConvertiblePromissoryNotesRecordedInEquity
0 USD
imvt Forgiveness Of Interest On Convertible Promissory Notes Recorded In Equity
ForgivenessOfInterestOnConvertiblePromissoryNotesRecordedInEquity
587000 USD
imvt Noncash Financing Activities Total
NoncashFinancingActivitiesTotal
0 USD
imvt Noncash Financing Activities Total
NoncashFinancingActivitiesTotal
36161000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
166000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
422000000.0 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-170500000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[B] Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, research and development costs and income taxes. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact that the COVID-19 pandemic has had on its operations and financial results as of December 31, 2020 and through the issuance of this report. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
[D] Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentration of credit risk include cash. As of December 31, 2020, the cash balance is kept in one banking institution that the Company believes is of high credit quality and is in excess of federally insured levels. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash.
CY2020Q4 imvt Number Of Sublease Agreements
NumberOfSubleaseAgreements
3 subleaseAgreement
CY2018Q4 imvt Sub Licensed Agreement Aggregate Purchase Price
SubLicensedAgreementAggregatePurchasePrice
37800000 USD
CY2020Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5982712 shares
CY2019Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11769573 shares
CY2020Q1 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
3000000.0 USD
CY2019Q4 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
420900000 USD
CY2019Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2800000 USD
imvt Business Combination Additional Financial Advisory Fees
BusinessCombinationAdditionalFinancialAdvisoryFees
2300000 USD
CY2019Q4 imvt Business Combination Share Price Threshold Trading Days
BusinessCombinationSharePriceThresholdTradingDays
20 tradingDay
CY2019Q4 imvt Business Combination Share Price Trading Period
BusinessCombinationSharePriceTradingPeriod
30 tradingDay
CY2019Q3 imvt Common Stock To Potential Forfeiture In The Event That The Milestones Are Not Achieved
CommonStockToPotentialForfeitureInTheEventThatTheMilestonesAreNotAchieved
1800000 shares
CY2020Q3 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
1800000 shares
CY2017Q4 imvt Upfront Payments
UpfrontPayments
30000000.0 USD
CY2017Q4 imvt Percentage Of Research And Development Costs
PercentageOfResearchAndDevelopmentCosts
0.50
CY2017Q4 imvt Percentage Of Research And Development Costs
PercentageOfResearchAndDevelopmentCosts
0.50
CY2017Q4 imvt Milestone Payments
MilestonePayments
10000000.0 USD
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2085000 USD
CY2020Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
859000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1445000 USD
CY2020Q4 imvt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
9527000 USD
CY2020Q1 imvt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
8332000 USD
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1231000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
224000 USD
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
516000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13281000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10938000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
378107 shares
CY2020Q4 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
200000 USD
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
700000 USD
CY2019Q4 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
400000 USD
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
1000000.0 USD
CY2019Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
250000 shares
CY2020Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0114
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0035
CY2019Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0090
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0034
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
1800000 shares
CY2020Q4 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
10000 shares
CY2020Q1 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
10000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5757732 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3873888 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4893006 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5283520 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0 shares
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5750000 shares
CY2020Q4 imvt Earnout Shares Reserved For Issuance
EarnoutSharesReservedForIssuance
0 shares
CY2020Q1 imvt Earnout Shares Reserved For Issuance
EarnoutSharesReservedForIssuance
20000000 shares
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10875718 shares
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
34917408 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11438290 shares
CY2020Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5719145 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
25.92
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2186215 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.50
CY2020Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
65800000 USD
CY2020Q2 imvt Class Of Warrant Or Right Canceled
ClassOfWarrantOrRightCanceled
61710 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3873888 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.33
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M13D
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28029000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2602268 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
114084 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.57
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.94
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
226233 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.86
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5757732 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M26D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
175578000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1372915 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
51828000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.81
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.02
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1152000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5992000 USD
CY2019Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1332000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13217000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4988000 USD
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
48900000 USD
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M12D
CY2020Q2 imvt Number Of Sublease Agreements
NumberOfSubleaseAgreements
2 subleaseAgreement
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4200000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4200000 USD
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.039
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2020Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
700000 USD
CY2020Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
500000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
700000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
295000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1198000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1104000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1132000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
47000 USD
CY2020Q4 imvt Lessee Operating Lease Liability To Be Paid Due After Year Four
LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
0 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3824000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
328000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3496000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2392000 USD

Files In Submission

Name View Source Status
0001764013-21-000018-index-headers.html Edgar Link pending
0001764013-21-000018-index.html Edgar Link pending
0001764013-21-000018.txt Edgar Link pending
0001764013-21-000018-xbrl.zip Edgar Link pending
exhibit101-bradmiddlekauff.htm Edgar Link pending
exhibit311-q3.htm Edgar Link pending
exhibit312-q3.htm Edgar Link pending
exhibit321-q3.htm Edgar Link pending
exhibit322-q3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_01.jpg Edgar Link pending
imvt-20201231.htm Edgar Link pending
imvt-20201231.xsd Edgar Link pending
imvt-20201231_cal.xml Edgar Link unprocessable
imvt-20201231_def.xml Edgar Link unprocessable
imvt-20201231_htm.xml Edgar Link completed
imvt-20201231_lab.xml Edgar Link unprocessable
imvt-20201231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending